Deadline Alert: Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

Core Viewpoint - Iovance Biotherapeutics, Inc. faces a class action lawsuit following a significant decline in its financial performance and misleading statements regarding its business operations and revenue guidance [1][2][3]. Financial Performance - For Q1 2025, Iovance reported total product revenue of $49.3 million, down from $73.7 million in the previous quarter, indicating a decline of approximately 33% [2]. - The company revised its full fiscal year 2025 revenue guidance from a range of $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [2]. Lawsuit Details - The class action lawsuit alleges that Iovance made materially false and misleading statements and failed to disclose adverse facts about its business, including delays in treatment timelines at new Authorized Treatment Centers (ATCs) and inefficiencies in patient identification and selection [3]. - The complaint highlights that these issues led to increased costs and lower revenue, contradicting the company's positive statements about its operations and prospects [3]. Legal Action - Investors who purchased Iovance securities during the specified Class Period (May 9, 2024, to May 8, 2025) have until July 14, 2025, to file a lead plaintiff motion in the class action lawsuit [1][4].